News Stem Cell Transplant More Effective for SPMS Than Medications: Study Stem Cell Transplant More Effective for SPMS Than Medications: Study More transplant recipients experience clinical improvements long term by Steve Bryson, PhD | December 23, 2022 Share this article: Share article via email Copy article link A stem cell transplant more effectively slowed disability worsening in people with active secondary progressive multiple sclerosis (SPMS) than anti-inflammatory treatments and disease-modifying therapies (DMTs), a study has found. More transplant recipients also experienced clinical improvements that were sustained after three and five years. After 10 years, disability scores improved slightly for transplanted patients compared with worse scores for patients on medications. āOur results are encouraging, because while current treatments for secondary progressive MS have modest or small benefits, our study found stem cell transplants may not only delay disability longer than many other MS medications, they may also provide a slight improvement in symptoms,ā Matilde Inglese, MD, PhD, study author and professor of neurology at the University of Genoa, in Italy, said in a press release from the American Academy of Neurology. The findings were published in the journal Neurology, in the study āHematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.ā Recommended Reading December 2, 2022 News by Margarida Maia, PhD Eating Lots of Acidic Foods Linked to Worse, Longer Depression in MS Stem cell transplant emerging as MS therapeutic approach Most MS patients are first diagnosed with relapsing-remitting MS (RRMS), characterized by relapses, or worsening of new symptoms for at least 24 hours, followed by periods of remission, in which symptoms ease or go away entirely. Over time, some RRMS patients transition to SPMS, where symptoms steadily worsen, with or without relapses. Autologous hematopoietic stem cell transplant (aHSCT) is an emerging therapeutic approach for MS that aims to reset the immune system to a healthy state without the autoimmune-related immune cells that drive MS. The procedure involves harvesting hematopoietic stem cells, also known as blood stem cells, from the patient before their immune system is significantly eradicated by medications. Cells are then returned to the same patient ā hence the name autologous ā in the form of a stem cell transplant to repopulate the immune system with healthy cells. āHematopoietic stem cell transplants have been previously found to delay disability in people with relapsing-remitting MS, but less is known about whether such transplants could help delay disability during the more advanced stage of the disease,ā Inglese said. To find out, Inglese and colleagues at sites across Italy compared the effect of aHSCT with anti-inflammatory medications and DMTs on disability worsening in people with active SPMS. our study found stem cell transplants may not only delay disability longer than many other MS medications, they may also provide a slight improvement in symptoms The researchers collected data from the Italian Bone Marrow Transplantation Study Group and the Italian MS Registry. Their analyses included 79 people with active SPMS who received a stem cell transplant after their SPMS diagnosis and 1,975 SPMS patients who were treated with medications, matched in age, sex, and disability level to the transplant patients. The medication group received either anti-inflammatory therapies, such as azathioprine, azathioprine, and cyclophosphamide, or approved MS DMTs, including interferon-based medications, glatiramer acetate (sold as Copaxone, among others), mitoxantrone, Gilenya (fingolimod), Tysabri (natalizumab), Aubagio (teriflunomide), Tecfidera (dimethyl fumarate), and Lemtrada (alemtuzumab). Participants were assessed using Expanded Disability Status Scale (EDSS) scores over 10 years. Disability worsening was defined as a sustained increase in EDSS scores lasting at least six months. In SPMS patients who underwent aHSCT, the time to a first disability worsening event was twice as long as those taking DMTs, with 62% of transplanted patients versus 46% of the medication group being free from sustained disability worsening at five years, a statistically significant difference. Recommended Reading December 5, 2022 News by Margarida Maia, PhD Newer Neurologic Therapies Costly, Less Likely to Be Used Disability improvements found in more transplant patients vs medications group Notably, significantly more patients in the aHSCT group experienced disability improvements, or an easing in symptoms, that were sustained for three years ā 34.7% vs. 4.6% in the medications group. After five years, the proportion of transplant patients who maintained improvements was still greater (19% vs. 4%). Over 10 years, EDSS scores dropped by 0.013 points per year (indicating improvement) after stem cell transplant compared to an increase of 0.16 points per year (worsening) for those on anti-inflammatory medications and DMTs. āThe use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared to standard immunotherapy,ā the researchers concluded. āOur study shows that hematopoietic stem cell transplants were associated with a slowing of disability progression and a higher likelihood of disability improvement compared to other therapies,ā said Inglese. āWhile these results are encouraging, they are not applicable to patients with secondary progressive MS who do not have signs of inflammatory disease activity [relapses].” “More research is needed in larger groups of people to confirm our findings,” Inglese added. Print This Page About the Author Steve Bryson, PhD Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor. Tags medications, SPMS, stem cell transplant
February 23, 2024 News by Margarida Maia, PhD Most MS patients stay relapse-free 6 years after stem cell transplant
February 20, 2024 News by Lindsey Shapiro, PhD Chronic inflammatory lesions linked to more aggressive MS in US study
February 12, 2024 News by Andrea Lobo, PhD Sharp lymphocyte drop seen quickly in SPMS patients on Mayzent